Emmaus Life Sciences, Inc. (EMMA)

↓ Download CSV

CIK 0000822370 · OTC · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

In fiscal 2025, Emmaus Life Sciences, Inc. reported revenue of $12.45M, down 25.2% from the prior year. The company ran a net loss, with a net margin of -60.2% and a gross margin of 93.1%. It held $21.44M in total assets against $85.04M in total liabilities.

Key ratios (FY2025)

93.1%
Gross margin
1.9%
Operating margin
-60.2%
Net margin
-25.2%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019201820172016
Revenue$12.45M$16.65M$29.60M$18.39M$20.61M$23.17M$22.75M$16.46M
Cost of Revenue$857.0K$1.20M$1.34M$2.59M$3.31M$2.25M$1.09M$993.0K$53.5K$5.5K
Gross Profit$11.60M$15.45M$28.25M$15.80M$17.30M$20.92M$21.66M$15.47M$75.0K
Operating Income$231.0K-$1.89M$3.54M-$6.59M-$6.13M-$32.0K-$4.51M-$8.45M-$7.10M-$3.77M
Net Income-$7.49M-$6.45M-$3.73M-$10.62M-$15.95M$1.35M-$54.84M-$72.59M-$7.11M-$5.94M
EPS (Diluted)$-0.12$-0.10$-0.07$-0.21$-0.32
Total Assets$21.44M$23.60M$35.18M$48.23M$56.73M$59.54M$59.46M$75.28M$6.10M$512.1K
Total Liabilities$85.04M$80.08M$82.94M$82.32M$78.18M$64.69M$70.51M$96.99M$1.55M$1.58M
Shareholders' Equity-$63.61M-$56.48M-$47.76M-$34.09M-$21.45M-$5.16M-$11.05M-$21.71M$18.29M-$1.06M
Cash & Equivalents$2.13M$1.39M$2.55M$2.02M$2.28M$2.49M$1.77M$3.90M$5.45M$318.2K
Operating Cash Flow-$11.0K-$2.29M-$1.50M-$5.07M-$1.25M-$2.45M-$4.52M-$5.63M-$4.79M-$2.98M
Capital Expenditures$1.0K$12.0K$17.0K$26.0K$73.0K$15.0K$60.0K$94.0K$127.9K$4.0K
Shares Outstanding70.19M63.87M61.85M49.58M49.31M48.99M48.47M37.34M4.30M1.94M